Last reviewed · How we verify
QRxPharma Inc. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Oxycodone HCl | Oxycodone HCl | marketed | Opioid analgesic | Mu (μ) opioid receptor | Pain Management | |
| Q8003 | Q8003 | phase 3 | kappa opioid receptor antagonist | kappa opioid receptor | Psychiatry |
Therapeutic area mix
- Pain Management · 1
- Psychiatry · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ain Shams University · 1 shared drug class
- Ajay Wasan, MD, Msc · 1 shared drug class
- Alza Corporation, DE, USA · 1 shared drug class
- Archimedes Development Ltd · 1 shared drug class
- Asbjørn Mohr Drewes · 1 shared drug class
- Astellas Pharma Inc · 1 shared drug class
- BioDelivery Sciences International · 1 shared drug class
- AdventHealth · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for QRxPharma Inc.:
- QRxPharma Inc. pipeline updates — RSS
- QRxPharma Inc. pipeline updates — Atom
- QRxPharma Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). QRxPharma Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/qrxpharma-inc. Accessed 2026-05-14.